BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 34654402)

  • 21. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
    Reddy K; Damek D; Gaspar LE; Ney D; Waziri A; Lillehei K; Stuhr K; Kavanagh BD; Chen C
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):655-60. PubMed ID: 22483738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial.
    Combs SE; Kieser M; Rieken S; Habermehl D; Jäkel O; Haberer T; Nikoghosyan A; Haselmann R; Unterberg A; Wick W; Debus J
    BMC Cancer; 2010 Sep; 10():478. PubMed ID: 20819220
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-term radiotherapy followed by adjuvant chemotherapy in poor-prognosis patients with glioblastoma.
    Muni R; Minniti G; Lanzetta G; Caporello P; Frati A; Enrici MM; Marchetti P; Enrici RM
    Tumori; 2010; 96(1):60-4. PubMed ID: 20437859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma.
    Lewitzki V; Klement RJ; Kosmala R; Lisowski D; Flentje M; Polat B
    Radiat Oncol; 2019 Dec; 14(1):227. PubMed ID: 31831026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypofractionated intensity-modulated radiotherapy using simultaneous integrated boost technique with concurrent and adjuvant temozolomide for glioblastoma.
    Yoon SM; Kim JH; Kim SJ; Khang SK; Shin SS; Cho YH; Jwa E; Park JH; Ahn SD
    Tumori; 2013; 99(4):480-7. PubMed ID: 24326836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis.
    Minniti G; Scaringi C; Lanzetta G; Terrenato I; Esposito V; Arcella A; Pace A; Giangaspero F; Bozzao A; Enrici RM
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):109-15. PubMed ID: 25442339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report.
    Biau J; Chautard E; De Schlichting E; Dupic G; Pereira B; Fogli A; Müller-Barthélémy M; Dalloz P; Khalil T; Dillies AF; Durando X; Godfraind C; Verrelle P
    Radiat Oncol; 2017 Dec; 12(1):197. PubMed ID: 29212499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma.
    Song A; Bar-Ad V; Martinez N; Glass J; Andrews DW; Judy K; Evans JJ; Farrell CJ; Werner-Wasik M; Chervoneva I; Ly M; Palmer JD; Liu H; Shi W
    J Neurooncol; 2020 May; 147(3):653-661. PubMed ID: 32206976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiotherapy with and without temozolomide in elderly patients with glioblastoma.
    Niyazi M; Schwarz SB; Suchorska B; Belka C
    Strahlenther Onkol; 2012 Feb; 188(2):154-9. PubMed ID: 22231634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
    Ashby LS; Smith KA; Stea B
    World J Surg Oncol; 2016 Aug; 14(1):225. PubMed ID: 27557526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
    Stupp R; Mason WP; van den Bent MJ; Weller M; Fisher B; Taphoorn MJ; Belanger K; Brandes AA; Marosi C; Bogdahn U; Curschmann J; Janzer RC; Ludwin SK; Gorlia T; Allgeier A; Lacombe D; Cairncross JG; Eisenhauer E; Mirimanoff RO; ;
    N Engl J Med; 2005 Mar; 352(10):987-96. PubMed ID: 15758009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Randomized Study of Short Course (One Week) Radiation Therapy with or without Temozolomide in Elderly and/or Frail Patients with Newly Diagnosed Glioblastoma (GBM).
    Thakur S; Kumar N; Salunke P; Ahuja C; Madan R
    Asian Pac J Cancer Prev; 2022 Jul; 23(7):2317-2323. PubMed ID: 35901337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience.
    Zhong L; Chen L; Lv S; Li Q; Chen G; Luo W; Zhou P; Li G
    Radiat Oncol; 2019 Jun; 14(1):104. PubMed ID: 31196126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
    Stupp R; Hegi ME; Neyns B; Goldbrunner R; Schlegel U; Clement PM; Grabenbauer GG; Ochsenbein AF; Simon M; Dietrich PY; Pietsch T; Hicking C; Tonn JC; Diserens AC; Pica A; Hermisson M; Krueger S; Picard M; Weller M
    J Clin Oncol; 2010 Jun; 28(16):2712-8. PubMed ID: 20439646
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme.
    Terasaki M; Eto T; Nakashima S; Okada Y; Ogo E; Sugita Y; Tokutomi T; Shigemori M
    J Neurooncol; 2011 Apr; 102(2):247-53. PubMed ID: 20640480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma.
    Tsien CI; Brown D; Normolle D; Schipper M; Piert M; Junck L; Heth J; Gomez-Hassan D; Ten Haken RK; Chenevert T; Cao Y; Lawrence T
    Clin Cancer Res; 2012 Jan; 18(1):273-9. PubMed ID: 22065084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of glioblastoma in elderly patients: an overview of current treatments and future perspective.
    Lanzetta G; Minniti G
    Tumori; 2010; 96(5):650-8. PubMed ID: 21302607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
    Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ;
    Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme.
    Cohen MH; Johnson JR; Pazdur R
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6767-71. PubMed ID: 16203762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Toxicity and outcome of radiotherapy with concomitant and adjuvant temozolomide in elderly patients with glioblastoma: a retrospective study.
    Saito K; Mukasa A; Narita Y; Tabei Y; Shinoura N; Shibui S; Saito N
    Neurol Med Chir (Tokyo); 2014; 54(4):272-9. PubMed ID: 24257502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.